Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is well-positioned in the regenerative medicine market with a diverse portfolio of products and a strong management team. While they may face short-term challenges due to changes in CMS reimbursement rates, their upcoming product ReNu has the potential for growth and the company is expected to benefit from CMS's revised LCDs. With a current undervaluation and potential for market consolidation, Organogenesis could be a strong investment opportunity.

Bears say

Organogenesis Holdings is facing significant short term margin and profitability impacts, with expected negative EBITDA in 2026 due to lower revenue. With a pureplay exposure to the reimbursement changes in the regenerative medicine space and a lower revenue growth profile compared to peers, a discount is warranted for the stock, which we have valued at approximately 1.4x EV/Sales for 2027E revenue and 1.2x for 2028E revenue. Additionally, there are significant risks associated with reimbursement changes, clinical product development, and market consolidation.

Organogenesis Holdings (ORGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 3 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.